EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Stargardt’s Disease: Molecular Pathogenesis and Current Therapeutic Landscape

Kunal Dayma, Kalpana Rajanala, Arun Upadhyay iD

International Journal of Molecular Sciences · 2025

DOI: 10.3390/ijms26147006 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, 2025. Verfasst von Kunal Dayma und 2 weiteren Autor:innen. Beteiligte Einrichtung: Ocugen India, 5th Floor, AYDIV IT Park, Financial District, Nanakramguda, Hyderabad 500032, Telangana, India. Hauptthemen laut MEDLINE: Stargardt Disease. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 137 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Stargardt’s disease (STGD1) is an autosomal recessive juvenile macular degeneration caused by mutations in the ABCA4 gene, impairing clearance of toxic retinoid byproducts in the retinal pigment epithelium (RPE). This leads to lipofuscin accumulation, oxidative stress, photoreceptor degeneration, and central vision loss. Over 1200 pathogenic/likely pathogenic ABCA4 variants highlight the genetic heterogeneity of STGD1, which manifests as progressive central vision loss, with phenotype influenced by deep intronic variants, modifier genes, and environmental factors like light exposure. ABCA4 variants also show variable penetrance and geographical prevalence. With no approved treatment, investigational therapies target different aspects of disease pathology. Small-molecule therapies target vitamin A dimerization (e.g., ALK-001), inhibit lipofuscin accumulation (e.g., soraprazan), or modulate the visual cycle (e.g., emixustat hydrochloride). Gene therapy trials explore ABCA4 supplementation including strategies like RNA exon editing (ACDN-01) and bioengineered ambient light-activated OPSIN. RORA gene therapy (Phase 2/3) addresses oxidative stress, inflammation, lipid metabolism, and complement system dysregulation. Trials like DRAGON (Phase 3, tinlarebant), STARLIGHT (phase 2, bioengineered OPSIN) show promise, but optimizing efficacy remains challenging. With the key problem of establishing genotype–phenotype correlations, the future of STGD1 therapy may rely on approaches targeting oxidative stress, lipid metabolism, inflammation, complement regulation, and genetic repair.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Stargardt DiseaseHumansGenetic TherapyATP-Binding Cassette TransportersMutationAnimalsOxidative Stress

Stichwörter der Autor:innen

ABCA4Stargardt’s diseasecomplement systemgene therapylipofuscinmacular degeneration

Substanzen

ABCA4 protein, humanATP-Binding Cassette Transporters

Autor:innen und Institutionen

  • Ocugen India, 5th Floor, AYDIV IT Park, Financial District, Nanakramguda, Hyderabad 500032, Telangana, India.
  • Ocugen, 11 Great Valley Parkway, Malvern, PA 19355, USA.

ORCID-Profile: Arun Upadhyay

Zitieren

APA

Dayma, K., Rajanala, K., & Upadhyay, A. (2025). Stargardt’s Disease: Molecular Pathogenesis and Current Therapeutic Landscape. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms26147006

Vancouver

Dayma K, Rajanala K, Upadhyay A. Stargardt’s Disease: Molecular Pathogenesis and Current Therapeutic Landscape. International Journal of Molecular Sciences. 2025. doi:10.3390/ijms26147006

BibTeX
@article{Dayma2025,
  author = {Dayma, Kunal and Rajanala, Kalpana and Upadhyay, Arun},
  title = {Stargardt’s Disease: Molecular Pathogenesis and Current Therapeutic Landscape},
  journal = {International Journal of Molecular Sciences},
  year = {2025},
  doi = {10.3390/ijms26147006}
}
Kostenlos starten →